...
首页> 外文期刊>Bone marrow transplantation >Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients
【24h】

Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients

机译:同种异体造血细胞移植接受者移植前寿命寿命预后的预后意义

获取原文
获取原文并翻译 | 示例
           

摘要

Quality of life (QOL) is an important outcome for hematopoietic cell transplantation (HCT) recipients. Whether pre-HCT QOL adds prognostic information to patient and disease related risk factors has not been well described. We investigated the association of pre-HCT QOL with relapse, non-relapse mortality (NRM), and overall mortality after allogeneic Ha. From 2003 to 2012, the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale instrument was administered before transplantation to 409 first allogeneic HCT recipients. We examined the association of the three outcomes with (1) individual QOL domains, (2) trial outcome index (TOI) and (3) total score. In multivariable models with individual domains, functional well-being (hazard ratio (HR) 0.95, P=0.025) and additional concerns (HR 1.39, P=0.002) were associated with reduced risk of relapse, no domain was associated with NRM, and better physical well-being was associated with reduced risk of overall mortality (HR 0.97, P= 0.04). TOI was not associated with relapse or NRM but was associated with reduced risk of overall mortality (HR 0.93, P=0.05). Total score was not associated with any of the three outcomes. HCT-comorbidity index score was prognostic for greater risk of relapse and mortality but not NRM. QOL assessments, particularly physical functioning and functional well-being, may provide independent prognostic information beyond standard clinical measures in allogeneic Ha recipients.
机译:生活质量(QOL)是造血细胞移植(HCT)受者的重要结果。在HCT QOL预先添加到患者和疾病相关风险因素是否尚未得到很好的描述。我们调查了HCT QoL的关联,在异构HA后的复发,非复发死亡率(NRM)和总体死亡率。从2003年到2012年,在移植前给409个同种异体HCT接受者施用癌症治疗 - 骨髓移植尺度仪的功能评估。我们审查了三个成果与(1)个人QOL域名的协会,(2)审判结果指数(TOI)和(3)总得分。在具有单个结构域的多变量模型中,功能福祉(HR)0.95,p = 0.025)和额外涉及(HR 1.39,P = 0.002)与降低复发风险,没有域与NRM相关,更好的身体福祉与总体死亡率的风险降低有关(HR 0.97,P = 0.04)。 TOI与复发或NRM无关,但与整体死亡率的风险降低有关(HR 0.93,P = 0.05)。总分与三种结果中的任何一个都没有。 HCT-合并指数评分预后是复发和死亡率的更大风险,但不是NRM。 QOL评估,特别是物理功能和功能福祉,可以提供超越异构HA受者的标准临床措施的独立预后信息。

著录项

  • 来源
    《Bone marrow transplantation》 |2015年第9期|共6页
  • 作者单位

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Quantitat Hlth Sci Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

    Cleveland Clin Taussig Canc Inst Blood &

    Marrow Transplant Program Cleveland OH 44195 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号